Halozyme Therapeutics Inc (NASDAQ: HALO) stock closed at $45.65 on 11/15/24 after a major decline of -15.4%. Moreover, this decline was accompanied by exceptionally high trading volume at 471% of normal. The stock has declined -23.5% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Halozyme Therapeutics has a very high Power Rating of 88 and a very high Appreciation Score of 98, producing the Highest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment